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OBJECTIVE—The objective of this study was to evaluate the performance of blood glucose
meters in diabetes associated with pregnancy (DP).
RESEARCH DESIGN AND METHODS—Finger-prick blood glucose levels measured
using six different glucose meters on 102 patients with DP attending an antenatal clinic were
compared with laboratory plasma glucose results. HbA1c and hematocrit were also measured.
RESULTS—The plasmaglucoserange was2.2–9.4mmol/L with hematocrit33–37%andmean
HbA1c 5.5% 6 0.56 (SD). All meters provided plasma equivalent results except one, which re-
ported whole blood glucose that was adjusted to plasma equivalent values. The absolute glucose
difference [meter 2 plasma glucose] was 0.232 6 0.69 to 0.725 6 0.62 mmol/L mean 6 SD and
bias ranged from 6.1 to 15.8%. Two meters were affected by hematocrit ,36% (P , 0.05).
CONCLUSIONS—Blood glucose meters in current use are not optimally accurate when
compared with plasma glucose measurement in DP. Recognition of this deviation is essential
to prevent inappropriate treatment of DP.
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I
t is increasingly recognized that very
modest levels of hyperglycemia can be
associated with adverse fetal outcomes
in diabetes associated with pregnancy
(DP) (1–4). Self-monitoring of blood glu-
cose using glucose meters and appropri-
ate diet/insulin therapy has been shown
to improve glycemic control and fetal/
maternal outcomes (2–6). There are no
evidence-based criteria for required accu-
racy of glucose meters for management of
diabetes or speciﬁcally for DP. However,
there are numerous recommendations
and analytical performance goals pro-
posed. The American Diabetes Associa-
tion (ADA) stipulates the most stringent
goals, aiming for an analytical error ,5%
or total error (user plus analytical) ,10%
(7–13). Standards Australia (ISO15197.2)
and the National Committee for Clinical
Laboratory Standards (NCCLS) recom-
mend less stringent goalsof 620% at glu-
cose concentration .4.2 mmol/L and
within 6 0.83 mmol/L bias at glucose
concentration ,4 . 2m m o l / L( 8 –13). Al-
though the performance of glucose meters
appears to be within the less stringent
NCCLS criteria for monitoring diabetes
outsidepregnancy,theglucosemeterper-
formance is variable when applied to DP
(9,10). Any difference in performance of
glucose meters would be particularly sig-
niﬁcant in the narrow therapeutic range
recommendedforDP(1–4).Thesefactors
together with recent changes to glucose
strip technology, including recalibration
to report plasma-equivalent results,
prompted us to evaluate the accuracy
of glucose meters in an antenatal clinic
setting.
RESEARCH DESIGN AND
METHODS—Finger-prick samples
were obtained from 102 patients attend-
ing an antenatal clinic for management of
DP in a 6-month period. Single-use lan-
cetswereused,andtheﬁrstdropofblood
was removed with a sterile tissue. Sub-
sequent drops from the same site were
appliedonto strips for simultaneousanal-
ysis on six different types of glucose
meters (duplicate for each) in random
order. Specialized diabetes research
nurses performed these tests at the time
ofroutinevenousbloodcollection,allow-
ing us to obtain plasma glucose, HbA1c,
and hematocrit results measured on the
same day. Type of diabetes and treatment
including vitamin intake were noted.
The meters were calibrated each day ac-
cording to manufacturer speciﬁcations.
T h ev e n o u sb l o o ds a m p l e sw e r ec e n t r i -
fuged and analyzed within 30 min of col-
lection.
Plasma glucose was analyzed in the
laboratory using Hexokinase/G6PD/ADP-
NADP/NADPH reference method (Modular-
PPE, Roche Diagnostics, Indianapolis, IN)
(14). Five glucose meters (Accu-Chek Ad-
vantage-II and Accu-Chek Performa with
GDH/PQQ strips, 2 OptiumXceed [with
GDH/NAD 5- and 20-s reading strips],
and the FreeStyle Lite with GDH/PQQ
strips) and asixth glucose meter Stat-Strip
with GO/NAD strips were used. Five me-
ters provided plasma-equivalent glucose
readings. The measurements from the
sixth meter that provided whole blood
glucose readings (Accu-Chek Advantage-
II)wereadjustedtoplasma-equivalentval-
ues for the comparison (13).
Statistical and clinical analysis
Imprecision was evaluated by replicate
analysis of glucose measurements on the
duplicate meters using plasma samples
(n = 20) with mean glucose concentration
5.6 mmol/L and low and mid control sol-
utions for each meter (n = 20). Accuracy
was evaluated using these meter readings
against the plasma glucose measured in
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BRIEF REPORTthe laboratory. The absolute glucose dif-
ference was calculated as = (meter 2
plasma glucose) in mmol/L, and the bias%
was calculated as = [(meter 2 plasma
glucose)/plasma glucose] 3 100. The
Bland-Altman method was undertaken
to examine the difference between glu-
cose meter and plasma glucose results.
To determine any inﬂuence in hematocrit
levels, the mean glucose differences were
stratiﬁed by hematocrit levels ,36 and
$36% and compared with a two sample
t test. All results are given as ranges and/or
mean 6 SD.
RESULTS—The 102 patients had three
types ofdiabetes:gestational diabetes(n =
84), type 2 diabetes (n =8 ) ,a n dt y p e1
diabetes (n = 10). Sixty-three were on in-
sulin, and the rest were on dietary treat-
ment. The range of various parameters
tested was: glucose 2.2–9.4 mmol/L, he-
matocrit 29–43%, and HbA1c 4.4–8.4%
(mean 5.5% 6 0.56). The imprecision,
given as percent coefﬁcient of variation
(CV%), and total error (user plus analyt-
ical) calculated as bias% + 1.96CV% is
given in Table 1.
The overall absolute meter variations
were 0.232 6 0.69 to 0.725 6 0.62
mmol/L and 6.10–15.76% bias when ex-
pressed as a percentage (Table 1). When
glucose readings were grouped by hemat-
ocrit levels a signiﬁcant difference (P ,
0.05) for the two OptiumXceed meters
at hematocrit ,36% was observed,
whereas the other four meters did not
have any signiﬁcant difference with
change in hematocrit (10).
CONCLUSIONS—This study shows
that that the current glucose meters are
not optimally accurate when compared
with plasma glucose measurement. Some
can vary by as much as 2 mmol/L, and this
may lead to misclassiﬁcation and inap-
propriate treatment of DP (Supplementary
Fig. 1 and Supplementary Fig. 2 and
modiﬁed Clarke’s Error Grids [15],
Supplementary Fig. 3) including over
treatment with insulin and under recog-
nition of hypoglycemia.
One of the main strengths of this
study is the use of ﬁnger-prick capillary
samples collected essentially, as they
would be by patients for comparing
with the laboratory results. This is some-
times required in the management of DP,
especially if there is doubt about meter
performance and poor correlation with
clinical assessment. The testing of a vari-
etyof meterswith newer enzyme/cofactor
systems and the capture of data over a
narrow range of blood glucose levels seen
during pregnancy, where relatively small
variations can be clinically important, are
the other strengths of this study. A single
strip lot number was used for each meter,
to minimize variability between lots as-
sociated with some strip systems. The
samples were collected between 09.00
and 12.30 h and immediate postprandial
(,1h)sampleswereexcludedtominimize
the known lag between ﬁnger-prick and
plasma glucose. Specialized diabetes
nurses performed the tests in this study.
It is recognized that in the hands of non-
specialized users there may be more day-
to-day variations in technique and meter
performance. However, it was not the
purpose of this study to measure the
effects of technical skills on results.
This study identiﬁes a signiﬁcant and
underemphasized clinical problem in the
management of DP. Awareness of the
potential inaccuracies of glucose readings
is important in advising DP patients on
diet and insulin adjustments. This study
demonstrates that some of the meter sys-
temsappeartohavetechnology-producing
results closer to ADA goals, which were
thought to be unrealistic or unattainable
when they were proposed (Table 1). Al-
though the ADA goals for performance
should remain as a target for manufac-
turers to improve their performance, in
our opinion meters with an analytical er-
ror (bias) ,10%, total error ,15%, and
no hematocrit interference would be min-
imum for monitoring and managing DP.
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Table 1—Difference between blood glucose meters and plasma blood glucose
Meters
Mean
difference*
(mmol/L)
SD
(mmol/L)
95% Limits of
agreement 6 2S D
Mean
bias
(%)†
Mean total
analytical
error
%bias
+1.96*
CV (%)
Coefﬁcient of
variation
between
meters (%)
ACA 0.361 0.55 20.749 1.470 8.99 14.87 20.220
OPT20s 0.572 0.66 20.747 1.890 13.08 26.21 2.597
ACP 0.385 0.57 20.758 1.528 9.04 15.65 20.299
OPT5s 0.725 0.62 20.523 1.972 15.76 32.14 20.796
FSL 0.232 0.69 21.157 1.622 6.37 17.07 1.416
STAT 0.256 0.54 20.817 1.329 6.10 12.29 20.623
ADA stipulates the most stringent goals, aiming for an analytical error ,5% or total error (user plus
analytical) ,10%. All meters were calibrated to provide plasma glucose results, except one that reported
capillary whole blood glucose, and adjusted plasma values were calculated as whole blood glucose = plasma
glucose3[12(0.00243HCT)]fortheAccu-ChekAdvantage-IImeter(13).ACA,Accu-ChekAdvantage-II
(Roche Diagnostics, Mannheim, Germany) strips Lot No.450808; OPT20s, OptiumXceed 20 s stripsLot No.
54277 (Abbott Diabetes Care, Alameda, CA); ACP, Accu-Chek Performa (Roche Diagnostics) strips Lot No.
320151; OPT5s, OptiumXceed 5 s strips Lot No. 99884–5 (Abbott Diabetes Care); FSL, FreeStyle Lite
(AbbottDiabetesCare)stripsLotNo.0820633;STAT,Stat-Strip(NovaBiomedical,Waltham,MA)stripsLot
No. 0308273249. *Mean difference = (mean of the meters 2 plasma glucose). †[(meter 2 plasma glucose/
plasma glucose)] 3 100.
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Glucose meters in DPAlfred Hospital (Sydney, Australia) for their
assistance in completing this project.
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